JP2023507764A - １ｐ３６欠失症候群の治療的処置のためのガボキサドール - Google Patents

１ｐ３６欠失症候群の治療的処置のためのガボキサドール Download PDF

Info

Publication number
JP2023507764A
JP2023507764A JP2022537866A JP2022537866A JP2023507764A JP 2023507764 A JP2023507764 A JP 2023507764A JP 2022537866 A JP2022537866 A JP 2022537866A JP 2022537866 A JP2022537866 A JP 2022537866A JP 2023507764 A JP2023507764 A JP 2023507764A
Authority
JP
Japan
Prior art keywords
gaboxadol
pharmaceutically acceptable
acceptable salt
day
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022537866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507764A5 (https=
Inventor
デューリング，マシュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of JP2023507764A publication Critical patent/JP2023507764A/ja
Publication of JP2023507764A5 publication Critical patent/JP2023507764A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
JP2022537866A 2019-12-18 2020-12-18 １ｐ３６欠失症候群の治療的処置のためのガボキサドール Pending JP2023507764A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962949551P 2019-12-18 2019-12-18
US62/949,551 2019-12-18
PCT/US2020/065801 WO2021127308A1 (en) 2019-12-18 2020-12-18 GABOXADOL FOR THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME

Publications (2)

Publication Number Publication Date
JP2023507764A true JP2023507764A (ja) 2023-02-27
JP2023507764A5 JP2023507764A5 (https=) 2023-12-25

Family

ID=76439052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022537866A Pending JP2023507764A (ja) 2019-12-18 2020-12-18 １ｐ３６欠失症候群の治療的処置のためのガボキサドール

Country Status (10)

Country Link
US (1) US11364228B2 (https=)
EP (1) EP4051272A4 (https=)
JP (1) JP2023507764A (https=)
KR (1) KR20220114572A (https=)
CN (1) CN114786669A (https=)
AU (1) AU2020405060A1 (https=)
CA (1) CA3164635A1 (https=)
IL (1) IL293924A (https=)
MX (1) MX2022007715A (https=)
WO (1) WO2021127308A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018520189A (ja) * 2015-07-17 2018-07-26 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ガボキサドールでの発達障害の処置方法
WO2018144827A1 (en) * 2017-02-03 2018-08-09 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of tinnitus
JP2019524816A (ja) * 2016-08-11 2019-09-05 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． てんかん性障害の処置のための方法および組成物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US20020165217A1 (en) 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
BRPI0410857A (pt) 2003-06-25 2006-07-04 Lundbeck & Co As H método para o tratamento de depressão, uso de gaboxadol, e, composição farmacêutica
US20050234093A1 (en) 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
US20070032553A1 (en) 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
US20050137222A1 (en) 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
JP2007530604A (ja) 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
US20080262029A1 (en) 2005-04-29 2008-10-23 H. Lundbeck A/S Acid and Base Salt Forms of Gaboxadol
DE102005020882A1 (de) 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20090269795A1 (en) 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
US20090048288A1 (en) 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
TW200920358A (en) 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
WO2010015037A1 (en) 2008-08-08 2010-02-11 Howard Florey Institute Therapeutic methods and compositions
EP2334299A1 (en) 2008-09-01 2011-06-22 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat
WO2014123909A1 (en) 2013-02-05 2014-08-14 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
EP3129506A4 (en) * 2014-04-09 2017-12-27 Lineagen, Inc. Genetic markers associated with chromosomal deletion and duplication syndromes
RS62007B1 (sr) 2014-06-06 2021-07-30 Ovid Therapeutics Inc Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 糖尿病および関連する状態の処置におけるガボキサドールの使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018520189A (ja) * 2015-07-17 2018-07-26 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ガボキサドールでの発達障害の処置方法
JP2019524816A (ja) * 2016-08-11 2019-09-05 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． てんかん性障害の処置のための方法および組成物
WO2018144827A1 (en) * 2017-02-03 2018-08-09 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of tinnitus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VALERIE K JORDAN ET AL, THE APPLICATION OF CLINICAL GENETICS, vol. 8, JPN6024053572, 2015, pages 189 - 200, ISSN: 0005651261 *

Also Published As

Publication number Publication date
WO2021127308A1 (en) 2021-06-24
CN114786669A (zh) 2022-07-22
MX2022007715A (es) 2022-07-19
KR20220114572A (ko) 2022-08-17
EP4051272A4 (en) 2023-01-04
US20210186938A1 (en) 2021-06-24
CA3164635A1 (en) 2021-06-24
US11364228B2 (en) 2022-06-21
IL293924A (en) 2022-08-01
EP4051272A1 (en) 2022-09-07
AU2020405060A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
US11975103B2 (en) Compositions of midodrine and methods of using the same
KR19990082429A (ko) 장염 질환을 치료하기 위한 니코틴의 결장 전달
JP6857647B2 (ja) クリティカル・ケア処置中に用いるための鎮静方法および非経腸製剤
CA3119258A1 (en) Abuse-resistant mucoadhesive devices for delivery of buprenorphine
AU2010282660B2 (en) Methods for iontophoretically treating nausea and migraine
ES2970294T3 (es) Tratamiento del prurito urémico
US20240252447A1 (en) Pharmaceutical formulations containing gaboxadol for therapeutic treatment
US20220110917A1 (en) Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders
US11364228B2 (en) Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
US11690829B2 (en) Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
KR20070061578A (ko) 눈물 및 침 건조증 치료용 의약 조성물
EA042135B1 (ru) Таблетка деферипрона с отсроченным высвобождением и способ ее изготовления
AU2015230711A1 (en) Methods for iontophoretically treating nausea and migraine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231215

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250729